ACTRN12605000207617CompletedPhase 2
A Randomised, Placebo-Controlled Intervention Trial of Omega-3 PUFA, (Fish Oils), in People with Ischaemic Stroke
Health Research Council (New Zealand)0 sites220 target enrollmentStarted: August 25, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 220
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 45 Years to ot stated (—)
- Sex
- All
Inclusion Criteria
- •1. CT confirmed first-ever or recurrent ischaemic stroke 2. Clinically stable with atheromatous disease history greater than 3 months.
Exclusion Criteria
- •1. Known intolerance or hypersensitivity to fish and /or fish oils. 2. Current use of fish oils (dietary supplements) 3. Known to be pregnant or breast feeding 4. Active disease causing malabsorption.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyAcute heart failure with iron deficiencyMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001467-36-PLVifor (International) Inc.650
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyAcute heart failure with iron deficiencyMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001467-36-ESVifor (International) Inc.1,110
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyEUCTR2016-001467-36-NLVifor (International) Inc.1,110
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyAcute heart failure with iron deficiencyMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001467-36-ITVIFOR (INTERNATIONAL) INC.1,110
Active, not recruiting
Phase 1
A study to compare the use of ferric carboxymaltose with placebo in patients with acute heart failure and iron deficiencyAcute heart failure with iron deficiencyMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000011689MedDRA version: 20.0Level: PTClassification code 10022970Term: Iron deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-001467-36-GBVifor (International) Inc.650